Scil Technology develops biopharmaceutical drugs by combining proteins with special formulation technologies for the treatment of various diseases

 

Since Scil Technology GmbH was founded more than 15 years ago, the company develops innovative biopharmaceuticals to fight disorders related to ageing. Cutting-edge biological science and applied research is used to develop novel therapies for patients suffering from age related degenerative and inflammatory disorders. The pipeline covers promising pre-clinical and clinical development programs in osteoarthritis, inflammatory joint disease, cartilage injury and severe gingival inflammation. License deals have been concluded with leading pharma companies for development programs in different indications.

Scil Technology is now seeking partnership with a major pharmaceutical company to exploit the full potential of its disease modifying arthritis program and to progress development as quickly as possible from bench to patients.